All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to CD28 and CD3ζ signaling domain. And the vector product was designed for the treatment of melanoma.
CAR Construction : Fig.1 FACS analysis of parental stably expressing wt (U87MG.wtEGFR). The negative control (irrelevant antibody) fluorescence is plotted on each panel (black line). Panousis, C., Rayzman, V. M., Johns, T. G., Renner, C., Liu, Z., Cartwright, G., ... & Scott, A. M. (2005). Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. British journal of cancer, 92(6), 1069-1077. |
CAR Construction : Fig.2 Immune effector function of mAb 806. Representative results from three separate experiments are shown. Panousis, C., Rayzman, V. M., Johns, T. G., Renner, C., Liu, Z., Cartwright, G., ... & Scott, A. M. (2005). Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. British journal of cancer, 92(6), 1069-1077. |
CAR Construction : 806 scFv-28ζ Fig.3 806 CAR T cells exhibit low or no affinity for EGFR expressed on primary astrocytes and keratinocytes. Individual bioluminescence was assessed in 806 and 2173 CAR T cell treated groups. Thokala, R., Binder, Z. A., Yin, Y., Zhang, L., Zhang, J. V., Zhang, D. Y., ... & O’Rourke, D. M. (2021). High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology, 11. |
CAR Construction : 806 scFv-28ζ Fig.4 Anti-tumor activity of 806 CAR T cells in in vivo. Individual bioluminescence was assessed in 806 and 2173 CAR T cell treated groups Thokala, R., Binder, Z. A., Yin, Y., Zhang, L., Zhang, J. V., Zhang, D. Y., ... & O’Rourke, D. M. (2021). High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology, 11. |
CAR Construction : 806 scFv-28ζ Fig.5 High fidelity GBM organoids demonstrate cross-reactivity of 806 CAR. wtEGFR staining in both GBO lines provided additional evidence of the cross-reactive nature of the 806 CAR. Thokala, R., Binder, Z. A., Yin, Y., Zhang, L., Zhang, J. V., Zhang, D. Y., ... & O’Rourke, D. M. (2021). High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology, 11. |
CAR Construction : 806 scFv-28ζ Fig.6 In vitro characterization of 806 EGFR CAR T cells. Antigen specific cytolytic activity of 806 and 2173 CAR T cells against cell lines expressing EGFR and its variants. Thokala, R., Binder, Z. A., Yin, Y., Zhang, L., Zhang, J. V., Zhang, D. Y., ... & O’Rourke, D. M. (2021). High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology, 11. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EGFR (806) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-LC098). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION